A focus on LBCL patients in partial remission in the CAR-T era
The treatment paradigm for large B-cell lymphoma (LBCL) has undergone significant changes in recent years. Patients who fail to achieve a complete response (CR) after first-line therapy (1L) or relapse within 12 months are considered to have a poor prognosis. For these individuals, new therapeutic o...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2025-11-01
|
| coleção: | Frontiers in Hematology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1675099/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
